Pro Medicus Ltd
(FRA:PMC)
€
109.56
+2.22 (+2.07%)
Market Cap: 11.71 Bil
Enterprise Value: 11.55 Bil
PE Ratio: 71.56
PB Ratio: 42.05
GF Score: 87/100 
Full Year 2026 Pro Medicus Ltd Earnings Call Transcript
Aug 18, 2026 / 01:00AM GMT
Release Date Price:
€116.3
(+11.14%)
Key Points
Positve
- Pro Medicus Ltd (PMCUF) achieved record financial results with revenue up to $261.7 million and underlying EBIT of $196 million, while expanding margins to just under 75%.
- The company secured its second-largest contract wins ever, with 9 new contracts in the US and 1 in Europe totaling $407 million, and completed 6 out of 6 renewals, maintaining a 100% client retention rate.
- Forward recurring revenue contracts over a 5-year window increased to $1.3 billion, providing strong revenue visibility and certainty for future growth.
- The company's cloud-based implementations are a key competitive advantage, with all US implementations since 2020 being 100% cloud-based, and the ability to complete large-scale projects in a fraction of the industry norm time.
- Pro Medicus Ltd (PMCUF) is expanding its product portfolio with new offerings in digital pathology and optimized reporting, and its cardiology option is gaining traction, positioning the company for further market penetration.
- The company maintains a strong balance sheet with cash and financial assets of $250 million, up nearly 20%, and increased its total dividend by 25.5% to $0.69 per share fully franked.
- Pro Medicus Ltd (PMCUF) is well-positioned in the AI space as a gatekeeper for image-based AI, with a capital-light strategy and partnerships for AI algorithms, including breast cancer detection pending FDA clearance.
- The company's pipeline remains robust with increased inbound RFPs across all market segments, and it has a strong presence in the US market with over 50% of the top 20 hospitals as clients.
- Pro Medicus Ltd (PMCUF) has a significant runway for growth, with its US market share at 11% of an estimated $690 million market, and it believes up to 85-90% of the market is addressable.
- The company's new reporting tool, Visage 7 Reporting, is expected to be a material revenue opportunity, with potential incremental pricing of 30-35% per exam, and it is already being implemented in Europe.
Negative
- Currency fluctuations had a material impact on financial results, with an $11.8 million hit to revenue and $9.9 million to EBIT, which could continue to affect reported figures.
- The company faces a radiologist shortage in the industry, which, while a driver for its productivity solutions, also poses a risk to overall market volume growth.
- Pro Medicus Ltd (PMCUF) has not finalized pricing for its new reporting tool, and there is competition from other reporting systems, which could lead to price pressure.
- The company's investments in AI companies, such as Pro Medicus and Echo IQ, are subject to share price volatility, and the final returns depend on future market conditions.
- Expansion in Europe is challenging due to smaller market opportunities, government funding constraints, and the region being behind the US in cloud adoption, limiting near-term growth potential.
- The company does not actively pursue markets like Japan and China due to regulatory hurdles and IP concerns, which limits its global addressable market.
- There is a risk that some potential clients may choose competitors based on price rather than value, as the company does not win every tender.
- The implementation of new contracts, such as Trinity, is complex and resource-intensive, and while on schedule, any delays could impact revenue recognition.
- The company's growth is dependent on the successful integration of new products like digital pathology and reporting, which are still in early stages and may face adoption challenges.
- Pro Medicus Ltd (PMCUF) faces potential competitive dynamics from AI providers like DeepHealth, which could either be partners or competitors, adding uncertainty to its AI strategy.
Operator
Good morning, and thank you for standing by. Welcome to the Pro Medicus Limited full year results briefing. (Operator Instructions)
I would now like to hand the conference over to Dr. Sam Hupert, CEO. Please go ahead.
Sam Hupert
Pro Medicus Limited - Chief Executive Officer, Managing Director, Executive Director
Thank you. Thanks, everybody, for joining us this morning for the full year results presentation. As you know, we currently work in 3 jurisdictions, Melbourne, our corporate headquarters and where we do our risk development. Germany, our R&D and support for the Visage product. And North America, which is over 90% of our revenues and our largest core of people.
So it's the biggest implementation group of people we have now overtaking both Europe and the US and Melbourne.
In terms of the highlights for the year, I think I won't go through all the financials. We have some other slides to deal with it. But we did win 1 contract in Europe and 9 in the US worth a total of $407 million at minimums. We completed 6 out of 6
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers